Eledon Pharmaceuticals, Inc. SEC filings ELDN

Eledon Pharmaceuticals, Inc. has 614 filings in SEC EDGAR's recent list, going back to Jun 18, 2007. Its latest annual report, Form ARS, was filed on Apr 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 13, 2026 (results of operations). The company's fiscal year ends on December 31.

Eledon Pharmaceuticals, Inc. SEC filings
Form Description Filed Period
S-8 Employee stock plan registration Sep 4, 2026 —
10-Q Quarterly report Aug 13, 2026 Jun 30, 2026
8-K Current report
Results of operations
Aug 13, 2026 Aug 13, 2026
8-K Current report
Bylaw or fiscal year change, Shareholder vote results
Jun 22, 2026 Jun 18, 2026
10-Q Quarterly report May 13, 2026 Mar 31, 2026
8-K Current report
Results of operations
May 13, 2026 May 13, 2026
EFFECT Filing May 11, 2026 —
CORRESP Letter to the SEC May 7, 2026 —
UPLOAD Letter from the SEC May 7, 2026 —
S-3 Shelf registration May 1, 2026 —
DEFA14A Additional proxy material Apr 30, 2026 —
ARS Annual report to shareholders Apr 30, 2026 Dec 31, 2025
DEF 14A Proxy statement Apr 30, 2026 Jun 18, 2026
PRE 14A Preliminary proxy statement Apr 21, 2026 Jun 18, 2026
10-K Annual report Mar 19, 2026 Dec 31, 2025
8-K Current report
Results of operations
Mar 19, 2026 Mar 19, 2026
8-K Current report
Unregistered share sale
Jan 2, 2026 Dec 30, 2025
8-K Current report
Results of operations
Nov 14, 2025 Nov 14, 2025
10-Q Quarterly report Nov 14, 2025 Sep 30, 2025
8-K Current report
Material agreement
Nov 13, 2025 Nov 12, 2025
424B5 Prospectus supplement Nov 13, 2025 —
424B5 Prospectus supplement Nov 12, 2025 —
8-K Current report
Results of operations, Regulation FD disclosure
Nov 7, 2025 Nov 6, 2025
10-Q Quarterly report Aug 14, 2025 Jun 30, 2025
10-Q/A Amended quarterly report Aug 14, 2025 Mar 31, 2025
10-K/A Amended annual report Aug 14, 2025 Dec 31, 2024
8-K Current report
Results of operations, Restatement
Aug 14, 2025 Aug 11, 2025
8-K Current report
Regulation FD disclosure
Aug 6, 2025 Aug 6, 2025
8-K Current report
Bylaw or fiscal year change, Shareholder vote results
Jun 12, 2025 Jun 10, 2025
10-Q Quarterly report May 14, 2025 Mar 31, 2025
8-K Current report
Results of operations
May 14, 2025 May 14, 2025
ARS Annual report to shareholders Apr 29, 2025 Dec 31, 2024
DEFA14A Additional proxy material Apr 29, 2025 —
DEF 14A Proxy statement Apr 29, 2025 Jun 10, 2025
PRE 14A Preliminary proxy statement Apr 14, 2025 Jun 10, 2025
8-K/A Amended current report
Auditor change
Apr 14, 2025 Apr 1, 2025
8-K Current report
Auditor change
Apr 7, 2025 Apr 1, 2025
10-K Annual report Mar 20, 2025 Dec 31, 2024
8-K Current report
Results of operations
Mar 20, 2025 Mar 20, 2025
8-K Current report
Officer or director change
Dec 20, 2024 Dec 16, 2024
10-Q Quarterly report Nov 12, 2024 Sep 30, 2024
8-K Current report
Results of operations
Nov 12, 2024 Nov 12, 2024
424B5 Prospectus supplement Oct 30, 2024 —
424B5 Prospectus supplement Oct 30, 2024 —
8-K Current report
Material agreement, Regulation FD disclosure
Oct 30, 2024 Oct 29, 2024
8-K Current report
Regulation FD disclosure
Oct 29, 2024 Oct 29, 2024
EFFECT Filing Oct 2, 2024 —
8-K Current report
Unregistered share sale
Oct 1, 2024 Sep 30, 2024
CORRESP Letter to the SEC Sep 30, 2024 —
UPLOAD Letter from the SEC Sep 26, 2024 —
8-K Current report
Material agreement
Sep 20, 2024 Sep 20, 2024
S-3 Shelf registration Sep 20, 2024 —
10-Q Quarterly report Aug 19, 2024 Jun 30, 2024
10-Q/A Amended quarterly report Aug 19, 2024 Mar 31, 2024
10-K/A Amended annual report Aug 19, 2024 Dec 31, 2023
8-K Current report
Results of operations, Restatement
Aug 14, 2024 Aug 13, 2024
NT 10-Q Filing Aug 14, 2024 Jun 30, 2024
8-K Current report
Auditor change
Jul 12, 2024 Jul 10, 2024
8-K Current report
Unregistered share sale
Jul 10, 2024 Jul 8, 2024
8-K Current report
Officer or director change, Shareholder vote results, Other events
Jul 10, 2024 Jul 10, 2024
424B3 Prospectus Jun 6, 2024 —
EFFECT Filing Jun 5, 2024 —
CORRESP Letter to the SEC Jun 3, 2024 —
UPLOAD Letter from the SEC May 30, 2024 —
ARS Annual report to shareholders May 30, 2024 Dec 31, 2023
DEFA14A Additional proxy material May 30, 2024 —
DEF 14A Proxy statement May 30, 2024 Jul 10, 2024
S-3 Shelf registration May 24, 2024 —
D Filing May 23, 2024 —
10-Q Quarterly report May 15, 2024 Mar 31, 2024
8-K Current report
Results of operations
May 13, 2024 May 9, 2024
8-K Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
May 7, 2024 May 6, 2024
10-K/A Amended annual report Apr 26, 2024 Dec 31, 2023
10-K Annual report Mar 28, 2024 Dec 31, 2023
8-K Current report
Results of operations
Mar 28, 2024 Mar 28, 2024
10-Q Quarterly report Nov 9, 2023 Sep 30, 2023
8-K Current report
Results of operations
Nov 9, 2023 Nov 9, 2023
8-K Current report
Regulation FD disclosure
Nov 2, 2023 Nov 2, 2023
8-K Current report
Officer or director change
Oct 2, 2023 Sep 29, 2023
8-K Current report
Officer or director change
Sep 21, 2023 Sep 20, 2023
8-K Current report
Officer or director change
Sep 13, 2023 Sep 11, 2023
S-8 Employee stock plan registration Aug 11, 2023 —
10-Q Quarterly report Aug 10, 2023 Jun 30, 2023
8-K Current report
Results of operations
Aug 10, 2023 Aug 10, 2023
8-K Current report
Officer or director change, Shareholder vote results
Jun 22, 2023 Jun 21, 2023
424B3 Prospectus Jun 8, 2023 —
EFFECT Filing Jun 2, 2023 —
CORRESP Letter to the SEC May 31, 2023 —
UPLOAD Letter from the SEC May 24, 2023 —
D Filing May 22, 2023 —
S-3 Shelf registration May 18, 2023 —
10-Q Quarterly report May 11, 2023 Mar 31, 2023
8-K Current report
Results of operations
May 11, 2023 May 11, 2023
DEF 14A Proxy statement May 1, 2023 —
ARS Annual report to shareholders May 1, 2023 Dec 31, 2022
DEFA14A Additional proxy material May 1, 2023 —
8-K Current report
Material agreement, Unregistered share sale, Officer or director change, Regulation FD disclosure
May 1, 2023 Apr 26, 2023
10-K Annual report Mar 30, 2023 Dec 31, 2022
8-K Current report
Results of operations
Mar 30, 2023 Mar 30, 2023
8-K Current report
Regulation FD disclosure
Jan 9, 2023 Jan 9, 2023
10-Q Quarterly report Nov 14, 2022 Sep 30, 2022
8-K Current report
Results of operations
Nov 14, 2022 Nov 14, 2022
10-Q Quarterly report Aug 11, 2022 Jun 30, 2022
8-K Current report
Results of operations
Aug 11, 2022 Aug 11, 2022
8-K Current report
Shareholder vote results
Jun 23, 2022 Jun 22, 2022
8-K Current report
Regulation FD disclosure, Other events
May 31, 2022 May 31, 2022
10-Q Quarterly report May 12, 2022 Mar 31, 2022
8-K Current report
Results of operations
May 12, 2022 May 12, 2022
DEFA14A Additional proxy material Apr 28, 2022 —
DEF 14A Proxy statement Apr 28, 2022 Jun 21, 2022
10-K Annual report Mar 24, 2022 Dec 31, 2021
8-K Current report
Results of operations
Mar 24, 2022 Mar 24, 2022
8-K Current report
Unregistered share sale
Jan 13, 2022 Jan 11, 2022
10-Q Quarterly report Nov 12, 2021 Sep 30, 2021
8-K Current report
Results of operations
Nov 12, 2021 Nov 12, 2021
10-Q Quarterly report Aug 12, 2021 Jun 30, 2021
8-K Current report
Results of operations
Aug 12, 2021 Aug 12, 2021
8-K Current report
Officer or director change
Aug 2, 2021 Jul 31, 2021
8-K Current report
Officer or director change
Jul 2, 2021 Jul 1, 2021
8-K Current report
Shareholder vote results
Jun 16, 2021 Jun 15, 2021
EFFECT Filing May 21, 2021 —
S-3/A Filing May 21, 2021 —
CORRESP Letter to the SEC May 18, 2021 —
10-Q Quarterly report May 14, 2021 Mar 31, 2021
8-K Current report
Results of operations
May 13, 2021 May 13, 2021
DEFA14A Additional proxy material Apr 29, 2021 —
DEF 14A Proxy statement Apr 29, 2021 Jun 15, 2021
8-K Current report
Other events
Apr 27, 2021 Apr 26, 2021
S-8 Employee stock plan registration Apr 12, 2021 —
UPLOAD Letter from the SEC Apr 5, 2021 —
S-3 Shelf registration Mar 31, 2021 —
10-K Annual report Mar 31, 2021 Dec 31, 2020
8-K Current report
Officer or director change
Mar 15, 2021 Mar 15, 2021
8-K Current report
Unregistered share sale
Jan 7, 2021 Dec 31, 2020
8-K Current report
Bylaw or fiscal year change, Other events
Jan 5, 2021 Jan 4, 2021
EFFECT Filing Dec 22, 2020 —
424B2 Prospectus Dec 22, 2020 —
8-K Current report
Shareholder vote results
Dec 22, 2020 Dec 18, 2020
CORRESP Letter to the SEC Dec 17, 2020 —
UPLOAD Letter from the SEC Dec 16, 2020 —
S-3 Shelf registration Dec 11, 2020 —
8-K Current report
Bylaw or fiscal year change
Dec 10, 2020 Dec 8, 2020
DEFA14A Additional proxy material Dec 10, 2020 —
UPLOAD Letter from the SEC Nov 20, 2020 —
8-K Current report
Bylaw or fiscal year change
Nov 20, 2020 Nov 20, 2020
8-K/A Amended current report Nov 20, 2020 Sep 9, 2020
DEF 14A Proxy statement Nov 20, 2020 Dec 18, 2020
10-Q Quarterly report Nov 16, 2020 Sep 30, 2020
CORRESP Letter to the SEC Nov 13, 2020 —
PRER14A Filing Nov 13, 2020 —
UPLOAD Letter from the SEC Nov 9, 2020 —
PRE 14A Preliminary proxy statement Oct 23, 2020 Oct 23, 2020
8-K Current report
Bylaw or fiscal year change
Oct 6, 2020 Oct 5, 2020
D Filing Sep 25, 2020 —
8-K Current report
Material agreement, Acquisition or sale of assets, Unregistered share sale, Officer or director change, Bylaw or fiscal year change, Regulation FD disclosure
Sep 15, 2020 Sep 9, 2020
424B3 Prospectus Sep 15, 2020 —
8-K Current report
Officer or director change
Sep 4, 2020 Sep 3, 2020
10-Q Quarterly report Aug 14, 2020 Jun 30, 2020
8-K Current report
Exit or restructuring costs, Officer or director change
Jun 17, 2020 Jun 11, 2020
8-K Current report
Results of operations
May 15, 2020 May 15, 2020
10-Q Quarterly report May 15, 2020 Mar 31, 2020
8-K Current report
Shareholder vote results
May 13, 2020 May 12, 2020
8-K Current report
Listing notice
Apr 23, 2020 Apr 21, 2020
EFFECT Filing Apr 3, 2020 —
CORRESP Letter to the SEC Apr 2, 2020 —
UPLOAD Letter from the SEC Mar 31, 2020 —
DEFA14A Additional proxy material Mar 31, 2020 —
DEF 14A Proxy statement Mar 31, 2020 May 12, 2020
S-8 Employee stock plan registration Mar 25, 2020 —
S-1 Registration statement Mar 25, 2020 —
8-K Current report
Results of operations
Mar 17, 2020 Mar 17, 2020
10-K Annual report Mar 17, 2020 Dec 31, 2019
PRE 14A Preliminary proxy statement Mar 16, 2020 May 12, 2020
8-K/A Amended current report
Unregistered share sale, Bylaw or fiscal year change
Feb 20, 2020 Feb 13, 2020
8-K Current report
Unregistered share sale, Bylaw or fiscal year change
Feb 19, 2020 Feb 13, 2020
8-K Current report
Listing notice
Feb 7, 2020 Feb 6, 2020
D Filing Jan 27, 2020 —
424B3 Prospectus Jan 16, 2020 —
8-K Current report
Material agreement, Unregistered share sale
Jan 16, 2020 Jan 10, 2020
424B3 Prospectus Jan 14, 2020 —
8-K Current report
Results of operations
Nov 13, 2019 Nov 13, 2019
10-Q Quarterly report Nov 13, 2019 Sep 30, 2019
8-K Current report
Results of operations
Aug 13, 2019 Aug 13, 2019
10-Q Quarterly report Aug 13, 2019 Jun 30, 2019
8-K Current report
Listing notice
Aug 9, 2019 Aug 8, 2019
8-K Current report
Auditor change, Officer or director change
Jul 12, 2019 Jul 11, 2019
S-8 Employee stock plan registration Jun 28, 2019 —
EFFECT Filing Jun 17, 2019 —
CORRESP Letter to the SEC Jun 14, 2019 —
UPLOAD Letter from the SEC Jun 12, 2019 —
S-1 Registration statement Jun 7, 2019 —
DEFA14A Additional proxy material May 15, 2019 —
DEF 14A Proxy statement May 15, 2019 Jul 11, 2019
8-K Current report
Results of operations
May 14, 2019 May 14, 2019
10-Q Quarterly report May 14, 2019 Mar 31, 2019
D Filing May 10, 2019 —
8-K Current report
Material agreement, Unregistered share sale, Other events
May 2, 2019 Apr 30, 2019
424B5 Prospectus supplement May 1, 2019 —
10-K/A Amended annual report Apr 30, 2019 Dec 31, 2018
8-K Current report
Other events
Apr 22, 2019 Apr 22, 2019

Showing 200 filings, the most recent 200. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
ELDN (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Irvine, CA
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1404281
Former names
Eledon Pharmaceuticals, Inc. (until Oct 30, 2026); Novus Therapeutics, Inc. (until Dec 22, 2020); Tokai Pharmaceuticals Inc (until May 4, 2017)

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.